vaccine, varicella-zoster




Zuellig Pharma
Concise Prescribing Info
Live attenuated Oka strain of varicella-zoster virus not <103.3 plaque-forming units (PFU)
Active immunisation against varicella of healthy subjects from 12 mth onwards, susceptible high-risk patients & their susceptible healthy close contacts.
Dosage/Direction for Use
SC Adult, adolescent ≥13 yr, childn 12 mth-12 yr, high-risk patient 2 doses w/ 2nd dose given at least 6 wk after 1st dose & not <4 wk.
Hypersensitivity to neomycin or after previous inj. Postpone vaccination in patients w/ acute severe febrile illness. Severe humoral or cellular immunodeficiency eg, patients w/ primary or acquired immunodeficiency states (total lymphocyte count <1,200/mm3); lack of cellular immune competence eg, leukaemia, lymphoma, blood dyscrasias, clinically manifest HIV infection; receiving immunosuppressants. Avoid pregnancy after 1 mth of vaccination.
Special Precautions
Anaphylactic reaction. Not to be administered intravascularly or intradermally. Syncope. Immunocompromised patients. Allow alcohol & other disinfecting agents to evaporate from skin prior to inj. Women of childbearing potential. Not to be used during pregnancy. Lactation.
Adverse Reactions
Pain, redness. Rash; inj site swelling, fever (oral/axillary ≥37.5°C; rectal ≥38°C).
Drug Interactions
Temporary depression of tuberculin skin sensitivity. Delay vaccination at least 3 mth in patients who have received immune globulins or blood transfusion. Reye's syndrome w/ salicylates. Short lived suppression of cell mediated immune response w/ measles vaccine. Not to be administered at the same time w/ other live attenuated vaccines.
MIMS Class
Vaccines, Antisera & Immunologicals
ATC Classification
J07BK01 - varicella, live attenuated ; Belongs to the class of varicella viral vaccines.
Varilrix vaccine 0.5 mL
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in